40045-50-9
40045-50-9
Chemical Structure
Halicin
Synonym(s): SU3327
- CAS No.: 40045-50-9
- Formula:C5H3N5O2S3
- Molecular Weight:261.30
IUPAC Name: 5-((5-nitrothiazol-2-yl)thio)-1,3,4-thiadiazol-2-amine
InChIKey: NQQBNZBOOHHVQP-UHFFFAOYSA-N
SMILES: NC1=NN=C(S1)SC2=NC=C([N+]([O-])=O)S2
Biological Activity: Halicin (SU3327) is a potent, selective and substrate-competitive JNK inhibitor with an IC50 of 0.7 μM. Halicin also inhibits protein-protein interactions between JNK and JNK Interacting Protein (JIP) with an IC50 of 239 nM. Halicin shows less active against p38α and Akt kinase[1][2].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Halicin | 98.92% | Halicin (SU3327) is a potent, selective and substrate-competitive JNK inhibitor with an IC50 of 0.7 μM. Halicin also inhibits protein-protein interactions between JNK and JNK Interacting Protein (JIP) with an IC50 of 239 nM. Halicin shows less active against p38α and Akt kinase. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Halicin (Standard) | ≥98% | Halicin (Standard) is the analytical standard of Halicin (HY-107597). This product is intended for research and analytical applications. Halicin (SU3327) is a potent, selective and substrate-competitive JNK inhibitor with an IC50 of 0.7 μM. Halicin also inhibits protein-protein interactions between JNK and JNK Interacting Protein (JIP) with an IC50 of 239 nM. Halicin shows less active against p38α and Akt Kinase. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. De SK, et al. Design, synthesis, and structure-activity relationship of substrate competitive, selective, and in vivo active triazole and thiadiazole inhibitors of the c-Jun N-terminal kinase. J Med Chem. 2009 Apr 9;52(7):1943-52. [Content Brief]
- [2]. Augustine C, et al. Traumatic injury elicits JNK-mediated human astrocyte retraction in vitro. Neuroscience. 2014 Aug 22;274:1-10. [Content Brief]
